Rebel Medicine Inc — SEC Form D Filing
Rebel Medicine Inc filed an SEC Form D on June 3, 2026, reporting $8.79M raised in Health Care.
Form D filing details
- Filing
- SEC Form D
- Filing date
- June 3, 2026
- Amount reported
- $8.79M
- Round stage
- Pre-Seed
- Industry
- Health Care
- Website
- https://www.rebelmedicine.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Acute pain management currently relies heavily on opioids, which can lead to addiction and other negative side effects. Additionally, rising healthcare costs and unequal access prevent many patients from receiving necessary treatments.
Solution
Rebel Medicine is developing Alevatrix™, a best-in-class long-acting local anesthetic for non-opioid postoperative pain management, to offer a more accessible and safer alternative for acute pain relief.
Verdict
Investors said yes because Rebel Medicine presented a compelling solution to a pressing problem, namely opioid dependency in pain management, not because they had a robust market entry strategy or a clear buyer. They were betting on the urgent need for safer alternatives in healthcare, while the limited upside lies in the competitive landscape of anesthetics and potential adoption hurdles within a regulated market. This cleared because stakeholders recognized the opioid crisis as a significant risk, not because Rebel Medicine had demonstrated a clear path to commercialization.
Source: SEC EDGAR Form D filing